Matthew Gline sold $23.4M of Roivant Sciences (ROIV)

Executed Sep 23 2024, disclosed Sep 24 2024, 1 day later.

Value, as filed

$23.4M

1,983,257 sh × $11.79

Executed

Sep 23 2024

the trade date, as filed

Disclosed

Sep 24 2024

1 day after the trade

Return, 21 sessionsiFrom the disclosed entry session; derived

–

purchases only

Returns are measured on stock purchases only.

The filer

Matthew Gline CEO profile →

Matthew Gline (CEO) filed 2 Form 4 reports in the trailing twelve months (0 purchases, 2 sales), most often in Roivant Sciences Ltd. (ROIV). The largest single filing was $37.7M of ROIV (1,740,000 sh across 3 lots, as filed), executed Dec 15 2025.

The name

ROIV

Roivant Sciences Ltd. ROIV · Healthcare · 75 filings in 24 months ticker →

Healthcare · Roivant Sciences Ltd., a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of medicine…

More Healthcare filings→ Insider filings, newest first→ View the original filing at www.sec.gov→

Other filings by Matthew Gline in ROIV

ROIVSALE Roivant Sciences Ltd. $8.4M
289,774 sh × $29.16
Exec Apr 16
Filed Apr 20 · 5:30 PM ET ROIVSALE Roivant Sciences Ltd. $37.7M
1,740,000 sh across 3 lots
Exec Dec 15 2025
Filed Dec 17 2025 · 5:30 PM ET